PROCEPT BioRobotics (NASDAQ:PRCT) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) announced its quarterly earnings data on Tuesday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.03, Zacks reports. The business had revenue of $83.33 million for the quarter, compared to the consensus estimate of $80.78 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.56%. The company’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. PROCEPT BioRobotics updated its FY 2026 guidance to EPS and its FY 2025 guidance to EPS.

PROCEPT BioRobotics Trading Down 9.7%

NASDAQ PRCT opened at $31.61 on Thursday. PROCEPT BioRobotics has a 12 month low of $31.14 and a 12 month high of $103.81. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.21 and a quick ratio of 7.86. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -20.66 and a beta of 0.98. The company’s fifty day moving average price is $36.37 and its two-hundred day moving average price is $47.93.

Wall Street Analyst Weigh In

A number of research firms have weighed in on PRCT. TD Cowen cut their price target on shares of PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday. Stephens began coverage on shares of PROCEPT BioRobotics in a research note on Wednesday, July 9th. They set an “overweight” rating and a $70.00 price target on the stock. Truist Financial cut their price target on shares of PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. Wall Street Zen raised shares of PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Finally, Oppenheimer raised shares of PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a research report on Tuesday, September 2nd. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $63.30.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC boosted its stake in PROCEPT BioRobotics by 90.7% during the 2nd quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock valued at $98,000 after acquiring an additional 810 shares during the last quarter. Osaic Holdings Inc. boosted its stake in PROCEPT BioRobotics by 20.3% during the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after acquiring an additional 337 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in PROCEPT BioRobotics by 709.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,266 shares of the company’s stock valued at $361,000 after acquiring an additional 5,492 shares during the last quarter. Prudential Financial Inc. boosted its stake in PROCEPT BioRobotics by 100.4% during the 2nd quarter. Prudential Financial Inc. now owns 6,815 shares of the company’s stock valued at $393,000 after acquiring an additional 3,415 shares during the last quarter. Finally, Brevan Howard Capital Management LP bought a new position in PROCEPT BioRobotics during the 2nd quarter valued at $407,000. 89.46% of the stock is currently owned by institutional investors.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).